(Navivumab)Biosimilar Reference Antibody-GS40462

货号：GS40462

Navivumab (also known as CT‑P23) is a human IgG1‑kappa monoclonal antibody that targets the hemagglutinin (HA) protein of influenza A viruses. It specifically binds to a conserved epitope within the stem‑fusion domain of the HA2 subunit. By binding to this region, navivumab inhibits the conformational changes required for viral‑host membrane fusion during entry, thereby neutralizing the virus. Its epitope conservation enables broad neutralization across multiple influenza A subtypes, including H1, H2, H5, and H9. It is being developed as a broad‑spectrum therapeutic and prophylactic agent for influenza A infection, with potential utility against seasonal and pandemic strains.